HBPCF News Alert Helix Biopharma Corp. (HBPCF) 1.3160 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 9:53 PM

Helix Biopharma Corp. (HBPCF) 1.3160 $HBPCF

Helix Announces Initiation of First Clinical Site for US Study
Marketwire Canada - Mon Dec 22, 3:32PM CST
Helix BioPharma (TSX: HBP) (FRANKFURT: HBP) announced today that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer ("LDOS001"

has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas. Helix also anticipates the participation of two additional sites in the United States. Helix anticipates that the first patient will be enrolled in the LDOS001 study in the first quarter of 2015.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix Announces the Results of Its Annual General Meeting
Marketwire Canada - Thu Dec 18, 4:20PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"

, a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that its Annual General Meeting (the "Meeting"

was held today as scheduled.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Announces Q1 Fiscal 2015 Results
Marketwire Canada - Mon Dec 15, 4:21PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2015, ended October 31, 2014.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. to Explore Growth Opportunities
Marketwire Canada - Thu Dec 04, 4:38PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company has begun a comprehensive exploration of growth opportunities available to it.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Announces Fiscal 2014 Results
Marketwire Canada - Thu Oct 23, 7:35PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2014.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Warts Therapeutics Pipeline Review 2014
M2 - Mon Oct 13, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc94mt/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Helix BioPharma Corp. - CEL-SCI Corporation - NanoViricides, Inc. - 3M Drug Delivery Systems - G&E Herbal Biotechnology Co., Ltd. - Anaconda Pharma - Foamix Ltd. - BioMAS Ltd. - ViroStatics, srl - Cutanea Life Sciences - Burke Pharmaceuticals, LLC - Agilvax, Inc. - Nielsen Biosciences, Inc. Drug Profiles - interferon alpha-2b (recombinant) - AS-101 - SRT-100 - AP-611074 - Candida Albicans Antigen - (digoxin furosemide) - Leukocyte Interleukin - A-101 - BURKE-201 - AX-03 - HerpeCide-I - imiquimod - 854-A - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts For more information visit http://www.researchandmarkets.com/research/wc...s_pipeline
CVM: 0.84 (-0.01), NNVC: 2.97 (-0.05)

Helix Reports on Interim Review of the Polish L-DOS47 Monotherapy Study in Non-Small Cell Lung Cancer
Marketwire Canada - Tue Sep 30, 7:31AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim data review of the first eight cohorts of the Company's ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"

.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Initiates Enrollment for Tenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Fri Sep 26, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the tenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"

.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
Marketwire Canada - Thu Sep 25, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at the 2nd Global Life Sciences Conference to be held on October 2, 2014 in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange. The conference is sponsored by WedBush Europe and WDM Capital. Over 100 of Central and Eastern Europe's top life science institutional investors, funds, and analysts are expected to attend the Conference.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
HBP: 3.20 (+0.02), HBP.TO: 1.53 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...